Glycemic Index of Date Cultivars and Date-based Products

December 24, 2025 updated by: Maha Alhussain, King Saud University

Assessment of the Glycemic Index of Various Saudi Date Cultivars and Date-based Products. in Healthy Adults

Dates are widely consumed worldwide and hold substantial cultural importance in many Middle Eastern communities. Despite growing interest in measuring the glycemic response and glycemic index of foods for both research and practical applications, studies examining the glycemic properties of different date cultivars and their derived products remain limited. This study aims to determine the glycemic index (GI) and glycemic load (GL) of commonly consumed Saudi date cultivars and their derived products in healthy subjects, and to evaluate their potential impact on postprandial glucose responses. The study will consist of 4 phases as follows: phase 1: Date varieties at Tamer stage; phase 2: date varieties at Rutab stage; phase 3: Date's debs; phase 4: Date's paste. For each phase, ten subjects will be asked to attend the laboratory in the morning after an overnight fast on several occasions. Each visit will be separated from the next by a "washout" day. The reference food, 50 g of glucose dissolve in 250 ml water will be tested on 3 alternating days to diminish day to day variation of glucose tolerance. 50g equivalent carbohydrates of dates will be consumed with 250 ml of water. Participants will be blinded to the type of the dates. Glucose will be measured in capillary blood samples following the two hours of the test meal consumption, at 15 min interval (0, 15, 30, 45, 60, 90 and 120 min) . A qualified technician will perform all blood glucose measurements.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy adults aged 18 to 55 years
  • Normotensive (normal blood pressure)
  • Normal fasting glucose levels
  • Not taking any prescription medication
  • Able and willing to provide written informed consent

Exclusion Criteria:

  • Morbid obesity (BMI > 40 kg/m²)
  • Pre-diabetic status
  • Pregnancy
  • Any gastrointestinal disorders
  • History of gastroenteritis within the preceding six months
  • Previous gastrointestinal surgeries
  • Smoking
  • Presence of chronic conditions (e.g., asthma, rheumatoid arthritis)
  • Presence of acute illnesses (e.g., respiratory or urinary tract infections)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Single Group - Crossover Consumption of Date Products and Glucose Reference
All participants will receive the glucose reference solution on three separate occasions and will consume the date or date-based product in individual sessions. Participants serve as their own control in a crossover design. Capillary blood glucose will be measured at several time points (0-120 minutes) after consumption to assess the glycemic index and load for each product.
Other: Date Cultivars and Date-based Products
Participants will consume 50 g of available carbohydrates from each date or date-based product, including 13 Tamer varieties, 12 Rutab varieties, 3 types of date paste, and 3 types of date molasses. Each product will be tested in a separate session.. The intervention will also include consumption of a glucose reference solution (50 g glucose) on three separate occasions.
Other Names:
  • Tamer
  • Rutab
  • Date paste
  • Date molasses

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Glycemic Index
Time Frame: Baseline (fasting) and up to 120 minutes post-consumption on each test day.
The glycemic index of each date cultivar and date-based product will be determined on designated test days by calculating the incremental area under the blood glucose response curve (iAUC) over the 120-minute postprandial period following consumption of a portion containing 50 g of available carbohydrates, relative to the iAUC of a reference glucose solution. Blood glucose measurements will be obtained at baseline (fasting) and at predefined time points up to 120 minutes after ingestion.
Baseline (fasting) and up to 120 minutes post-consumption on each test day.

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Glycemic Load (GL) of Fresh and Processed Date Products
Time Frame: Baseline (fasting) and up to 120 minutes post-consumption on each test day.
The glycemic load of each date-based product will be calculated on each test day using the measured glycemic index and the available carbohydrate content of a typical serving, based on blood glucose measurements obtained at baseline and up to 120 minutes post-consumption.
Baseline (fasting) and up to 120 minutes post-consumption on each test day.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
King Saud University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Maha Alhussain, PhD, King Saud University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 16, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 25, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 25, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 3, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 3, 2025

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 16, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 31, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 24, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 24/1428

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Notably, individual participant data will not be shared to ensure the privacy and confidentiality of the study participants. The data includes personal health information and making them publicly available might risk the identification of participants despite efforts to anonymize them.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings